Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Hadfield

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
International Journal of Molecular Sciences|February 25, 2023
Advances in Liquid Biopsy Technology and Implications for Pancreatic CancerAlexander G Raufi, Michael S May, Matthew J Hadfield, et al.
Current Oncology Reports|June 3, 2025
Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic TargetsKelly Pan, A Maria Vromans, Liang Cheng, et al.
Oncogene|January 28, 2024
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)Matthew J Hadfield, Howard Safran, Marco A Purbhoo, et al.
Cancer|November 15, 2019
Neurologic complications of melanomaJustine V Cohen, Nancy Wang, Vyshak A Venur, et al.
NPJ Precision Oncology|November 14, 2025
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancerClaire Lin, Matthew J Hadfield, Ariana Santopietro, et al.
Clinical Therapeutics|June 2, 2026
Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor Associated Renal Toxicities: A Retrospective Pan-Cancer Cohort StudyCharmi Trivedi, Julia Contini, MacKenzie Adams, et al.
Cancer Treatment Reviews|December 2, 2025
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancerClaire Lin, Matthew J Hadfield, Amol Rathore, et al.
Cancer Research Communications|November 13, 2025
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Andre L De Souza, Matthew J Hadfield, Shaolei Lu, et al.
The Lancet. Oncology|July 18, 2024
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort studyGuihong Wan, Wenxin Chen, Sara Khattab, et al.
Cell Reports. Medicine|April 9, 2024
Harnessing artificial intelligence for prostate cancer managementLingxuan Zhu, Jiahua Pan, Weiming Mou, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Molecular Sciences|February 25, 2023
Advances in Liquid Biopsy Technology and Implications for Pancreatic CancerAlexander G Raufi, Michael S May, Matthew J Hadfield, et al.
Current Oncology Reports|June 3, 2025
Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic TargetsKelly Pan, A Maria Vromans, Liang Cheng, et al.
Oncogene|January 28, 2024
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)Matthew J Hadfield, Howard Safran, Marco A Purbhoo, et al.
Cancer|November 15, 2019
Neurologic complications of melanomaJustine V Cohen, Nancy Wang, Vyshak A Venur, et al.
NPJ Precision Oncology|November 14, 2025
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancerClaire Lin, Matthew J Hadfield, Ariana Santopietro, et al.
Clinical Therapeutics|June 2, 2026
Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor Associated Renal Toxicities: A Retrospective Pan-Cancer Cohort StudyCharmi Trivedi, Julia Contini, MacKenzie Adams, et al.
Cancer Treatment Reviews|December 2, 2025
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancerClaire Lin, Matthew J Hadfield, Amol Rathore, et al.
Cancer Research Communications|November 13, 2025
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Andre L De Souza, Matthew J Hadfield, Shaolei Lu, et al.
The Lancet. Oncology|July 18, 2024
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort studyGuihong Wan, Wenxin Chen, Sara Khattab, et al.
Cell Reports. Medicine|April 9, 2024
Harnessing artificial intelligence for prostate cancer managementLingxuan Zhu, Jiahua Pan, Weiming Mou, et al.
Pageof 4